A randomized, double-blind, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA [hydrofluoroalkane] (2 inhalations of 50/25mcg) twice daily compared with fluticasone propionate 100mcg HFA (2 Inhalations of 50mcg) twice daily in subjects 4-11 years of age with persistent asthma

Trial Profile

A randomized, double-blind, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA [hydrofluoroalkane] (2 inhalations of 50/25mcg) twice daily compared with fluticasone propionate 100mcg HFA (2 Inhalations of 50mcg) twice daily in subjects 4-11 years of age with persistent asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2015

At a glance

  • Drugs Fluticasone propionate; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Oct 2008 Actual start date changed from Oct 2006 to Feb 2007 as reported by ClinicalTrials.gov.
    • 14 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top